VhH anti‐thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow
暂无分享,去创建一个
C. Maas | R. Schiffelers | R. Urbanus | J. Meijers | Marc van Moorsel | C. A. Koekman | Geke Poolen | S. Verhoef | S. de Maat | A. Barendrecht | Nadine D van Kleef | Nadine D. van Kleef | M. V. van Moorsel | Geke C Poolen
[1] P. Declerck,et al. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review , 2021, International journal of molecular sciences.
[2] C. Maas,et al. A head-to-head comparison of conjugation methods for VHHs: Random maleimide-thiol coupling versus controlled click chemistry , 2019, International journal of pharmaceutics: X.
[3] E. Conway,et al. Exploring traditional and nontraditional roles for thrombomodulin. , 2018, Blood.
[4] C. Maas,et al. Live-cell Imaging of Platelet Degranulation and Secretion Under Flow. , 2017, Journal of visualized experiments : JoVE.
[5] A. Gils,et al. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice , 2016, Stroke.
[6] P. Liaw,et al. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells , 2016, Journal of thrombosis and haemostasis : JTH.
[7] S. Muyldermans,et al. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody , 2014, Thrombosis and Haemostasis.
[8] C. Maas,et al. Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy , 2014, Circulation.
[9] C. Maas,et al. A nanobody-based method for tracking factor XII activation in plasma , 2013, Thrombosis and Haemostasis.
[10] S. Muyldermans,et al. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor , 2010, Journal of thrombosis and haemostasis : JTH.
[11] S. Diamond,et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear‐resistance of platelet aggregates , 2008, Journal of thrombosis and haemostasis : JTH.
[12] E. Bird,et al. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis , 2007, Journal of Thrombosis and Thrombolysis.
[13] H C Hemker,et al. The limits of simulation of the clotting system , 2006, Journal of thrombosis and haemostasis : JTH.
[14] A. Gils,et al. Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors , 2005, Journal of thrombosis and haemostasis : JTH.
[15] F. Rosendaal,et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. , 2004, Blood.
[16] J. Weitz,et al. Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin* , 2003, Journal of Biological Chemistry.
[17] H. Coenraad Hemker,et al. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.
[18] C. Kluft,et al. Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro * , 2003, The Journal of Biological Chemistry.
[19] M. Nesheim,et al. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis , 2003, Journal of thrombosis and haemostasis : JTH.
[20] C. Esmon,et al. The protein C pathway , 2000, Chest.
[21] A. Hamsten,et al. Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery Disease , 2000, Thrombosis and Haemostasis.
[22] Weiqi Wang,et al. Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation* , 2000, The Journal of Biological Chemistry.
[23] F. Rosendaal,et al. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.
[24] J. Shafer,et al. Characterization of Plasmin-mediated Activation of Plasma Procarboxypeptidase B , 1999, The Journal of Biological Chemistry.
[25] M. Nagashima,et al. Identification and Characterization of Two Thrombin-activatable Fibrinolysis Inhibitor Isoforms , 1998, Thrombosis and Haemostasis.
[26] K. Kokame,et al. Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein C* , 1998, The Journal of Biological Chemistry.
[27] P. A. von dem Borne,et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. , 1997, The Journal of clinical investigation.
[28] P. Simioni,et al. An Antifibrinolytic Mechanism Describing the Prothrombotic Effect Associated with Factor VLeiden* , 1996, The Journal of Biological Chemistry.
[29] P. A. von dem Borne,et al. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. , 1995, Blood.
[30] J. Parkinson,et al. Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity. , 1993, The Journal of biological chemistry.
[31] G. Broze,et al. Factor XI activation in a revised model of blood coagulation , 1991, Science.
[32] E. Davie,et al. Factor XI deficiency in Ashkenazi Jews in Israel. , 1991, The New England journal of medicine.
[33] K Fujikawa,et al. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. , 1991, The Journal of biological chemistry.
[34] S. Yamamoto,et al. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. , 1989, The Journal of biological chemistry.
[35] E. Conway. Thrombomodulin and its role in inflammation , 2011, Seminars in Immunopathology.
[36] B. Bouma,et al. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis? , 2006, Annals of medicine.
[37] M. Halks-Miller,et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. , 2002, The Journal of clinical investigation.
[38] J. Meijers,et al. Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin , 2001, Thrombosis and Haemostasis.
[39] C. Cambillau,et al. Camelid heavy-chain variable domains provide efficient combining sites to haptens. , 2000, Biochemistry.